Company receives the Platinum Award for Innovator in Biotech Solutions CategorySHELTON, Conn., April 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (NASDAQ:INTS) (&#34;Intensity&#34; or the &#34;Company&#34;), a

<p xmlns="http://www.w3.org/1999/xhtml" class="prntac"><i xmlns="http://www.w3.org/1999/xhtml">Company receives the Platinum Award for Innovator in Biotech Solutions Category</i></p><p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">SHELTON, Conn.</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">April 15, 2026</span> /PRNewswire/ -- <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4664422-1&amp;h=1027066789&amp;u=http%3A%2F%2Fwww.intensitytherapeutics.com%2F&amp;a=Intensity+Therapeutics%2C+Inc." target="_blank" rel="nofollow">Intensity Therapeutics, Inc.</a>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/INTS">INTS</a>) (&#34;Intensity&#34; or the &#34;Company&#34;), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, announces it has been named a winner of the <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4664422-1&amp;h=1490964244&amp;u=https%3A%2F%2Fwww.pinnacle-award.com%2Fwinners&amp;a=2026+Pinnacle+Awards+for+Healthcare" target="_blank" rel="nofollow">2026 Pinnacle Awards for Healthcare</a> for its intratumoral injection platform and lead drug candidate INT230-6.</p>
    <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
                <p xmlns="http://www.w3.org/1999/xhtml">
                        <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/2290007/Intensity_Therapeutics_Inc_Logo.html" target="_blank" rel="nofollow">
                    <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/2290007/Intensity_Therapeutics_Inc_Logo.jpg" title="Logo (PRNewsfoto/Intensity Therapeutics Inc.)" alt="Logo (PRNewsfoto/Intensity Therapeutics Inc.)"></img>
                        </a>
                </p>
    </div>
<p xmlns="http://www.w3.org/1999/xhtml">The Company was selected a Platinum award winner in the Innovator in Biotech Solutions Category. INT230-6, Intensity&#39;s lead proprietary investigational product candidate, is designed for direct intratumoral injection. The drug consists of two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate, and a diffusion and cell penetration enhancer molecule (&#34;SHAO&#34;) that non-covalently conjugates to the two payload drugs, facilitating the dispersion of potent cytotoxic drugs throughout tumors and allowing the active agents to diffuse into cancer cells. INT230-6 is being developed in combination with standard-of-care therapies to improve the durability of response across multiple solid tumor indications.</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;The recognition from the Pinnacle Award is a testament to Intensity&#39;s commitment to changing the future of cancer care,&#34; said Intensity Therapeutics Co-Founder and CEO Lewis H. Bender. &#34;INT230-6 represents a new, unique methodology for cancer cell death that holds the potential to shift the cancer treatment from a short-term death sentence to chronic diseases, even for malignancies that are unresponsive to immunotherapy.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">The Pinnacle Awards is an esteemed annual awards program dedicated to recognizing and celebrating outstanding achievements across various industries. Its mission is to honor companies, products, and individuals that have demonstrated exceptional innovation, creativity, and impact in their fields. Each year, nominees are evaluated by industry experts, media professionals, and consultants who ensure that only the most deserving candidates receive recognition.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About Intensity Therapeutics</b></p><p xmlns="http://www.w3.org/1999/xhtml">Intensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor&#39;s dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity&#39;s clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases even for malignancies that do not respond to conventional immunotherapy. Intensity has completed two clinical studies that enrolled over 200 patients using INT230-6: a Phase 1/2 dose escalation study in metastatic cancers including sarcomas (NCT03058289), and a Phase 2 randomized control clinical trial in locally advanced breast cancer (the &#34;INVINCIBLE-2 Study&#34;) (NCT04781725) in women without undergoing chemotherapy prior to their surgery. The Company initiated a Phase 3 trial in soft tissue sarcoma (the &#34;INVINCIBLE-3 Study&#34;) (NCT06263231), testing INT230-6 as second or third-line monotherapy compared to the SOC with overall survival as an endpoint. Intensity also initiated a Phase 2 study in collaboration with The Swiss Group for Clinical Cancer Research, formerly SAKK, now the Swiss Cancer Institute (the &#34;INVINCIBLE-4 Study&#34;) (NCT06358573) as part of a Phase 2/3 program evaluating INT230-6 followed by the SOC immunochemotherapy and the SOC alone for patients with presurgical triple-negative breast cancer. The pathological complete response rate is the endpoint. For more information about Intensity, including publications, papers, and posters about its novel approach to cancer therapeutics, visit <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.intensitytherapeutics.com" rel="nofollow">www.intensitytherapeutics.com</a> or review our SEC filings.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</b></p><p xmlns="http://www.w3.org/1999/xhtml">Certain statements in this press release may constitute &#34;forward-looking statements&#34; within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Company&#39;s expected future plans, cash runway, development activities, projected milestones, business activities or results. When or if used in this communication, the words &#34;may,&#34; &#34;could,&#34; &#34;should,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;predict&#34; and similar expressions and their variants, as they relate to the Company or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management&#39;s current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the initiation, timing, progress and results of future preclinical studies and clinical trials and research and development programs; the need to raise additional funding before the Company can expect to generate any revenues from product sales; plans to develop and commercialize product candidates; the timing or likelihood of regulatory filings and approvals; the ability of the Company&#39;s research to generate and advance additional product candidates; the risk that product candidates that appear promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials; the implementation of the Company&#39;s business model, strategic plans for the Company&#39;s business, product candidates and technology; commercialization, marketing and manufacturing capabilities and strategy; the rate and degree of market acceptance and clinical utility of the Company&#39;s system; the Company&#39;s competitive position; the Company&#39;s intellectual property position; developments and projections relating to the Company&#39;s competitors and its industry; the Company&#39;s ability to maintain and establish collaborations or obtain additional funding; expectations related to the use of cash and cash equivalents and investments; our potential inability to satisfy the Nasdaq Capital Market&#39;s requirements for continued listing and be subject to delisting; estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other risks described in the section entitled &#34;Risk Factors&#34; in the Company&#39;s Annual Report on Form 10-K for the year ended December 31, 2024 and in the Company&#39;s subsequent SEC ﬁlings, which can be obtained on the SEC website at <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.sec.gov" rel="nofollow">www.sec.gov</a>. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management&#39;s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Investor Relations Contact:</b></p><p xmlns="http://www.w3.org/1999/xhtml">Justin Kulik<br xmlns="http://www.w3.org/1999/xhtml"></br>CORE IR<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:INTS@coreir.com" target="_blank" rel="nofollow">INTS@coreir.com<br xmlns="http://www.w3.org/1999/xhtml"></br></a>(516) 222-2560</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Media Contact:</b></p><p xmlns="http://www.w3.org/1999/xhtml">Matt Cossel<br xmlns="http://www.w3.org/1999/xhtml"></br>CORE IR<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:pr@coreir.com" target="_blank" rel="nofollow">pr@coreir.com</a></p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=NE34373&amp;sd=2026-04-15"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/intensity-therapeutics-recognized-with-pinnacle-award-for-excellence-in-healthcare-innovation-302742689.html" target="_blank">https://www.prnewswire.com/news-releases/intensity-therapeutics-recognized-with-pinnacle-award-for-excellence-in-healthcare-innovation-302742689.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE Intensity Therapeutics Inc.</p>

INTS

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Intensity Therapeutics Wins Pinnacle Award for Innovation in Cancer Treatment

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Company receives the Platinum Award for Innovator in Biotech Solutions CategorySHELTON, Conn., April 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (NASDAQ:INTS) (&amp;#34;Intensity&amp;#34; or the &amp;#34;Company&amp;#34;), a</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Intensity Therapeutics has been awarded the 2026 Pinnacle Award for its innovative intertumoral injection platform and lead candidate, INT230-6. This recognition may enhance investor confidence and help solidify the company’s position in the competitive biotechnology market.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Intensity Therapeutics wins 2026 Pinnacle Award for Biotech Innovations.</li><li>INT230-6, the lead candidate, uses a unique intratumoral injection platform.</li><li>Award recognizes commitment to improving cancer treatment methodologies.</li><li>INT230-6 targets solid tumors, enhancing immune response against cancers.</li><li>Company&#039;s clinical trials suggest potential paradigm shift in cancer therapy.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Intensity Therapeutics, Inc. (INTS)</strong>: The company’s recognition may lead to improved investor sentiment and valuation.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under &#039;Corporate Developments&#039; as it highlights a significant achievement for Intensity Therapeutics, which could influence market perception and investment decisions.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Recognition at the Pinnacle Awards elevates Intensity&#039;s industry profile.</li><li>Success of INT230-6 could drive future funding and partnership opportunities.</li><li>Increased investor interest expected due to improved market perception.</li><li>Potential for accelerated trial enrollment as awareness grows.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Award received on April 15, 2026.</li><li>INT230-6 is under clinical trials for multiple solid tumor indications.</li><li>Over 200 patients enrolled in completed clinical studies.</li><li>Phase 3 trial initiated for soft tissue sarcoma.</li><li>CEO highlights INT230-6&#039;s potential to change cancer treatment paradigms.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>INTS is likely to see positive price momentum in the near term due to award recognition.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml" class="prntac"><i xmlns="http://www.w3.org/1999/xhtml">Company receives the Platinum Award for Innovator in Biotech Solutions Category</i></p><p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">SHELTON, Conn.</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">April 15, 2026</span> /PRNewswire/ -- <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4664422-1&amp;h=1027066789&amp;u=http%3A%2F%2Fwww.intensitytherapeutics.com%2F&amp;a=Intensity+Therapeutics%2C+Inc." target="_blank" rel="nofollow">Intensity Therapeutics, Inc.</a>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/INTS">INTS</a>) (&#34;Intensity&#34; or the &#34;Company&#34;), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, announces it has been named a winner of the <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4664422-1&amp;h=1490964244&amp;u=https%3A%2F%2Fwww.pinnacle-award.com%2Fwinners&amp;a=2026+Pinnacle+Awards+for+Healthcare" target="_blank" rel="nofollow">2026 Pinnacle Awards for Healthcare</a> for its intratumoral injection platform and lead drug candidate INT230-6.</p>
    <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
                <p xmlns="http://www.w3.org/1999/xhtml">
                        <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/2290007/Intensity_Therapeutics_Inc_Logo.html" target="_blank" rel="nofollow">
                    <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/2290007/Intensity_Therapeutics_Inc_Logo.jpg" title="Logo (PRNewsfoto/Intensity Therapeutics Inc.)" alt="Logo (PRNewsfoto/Intensity Therapeutics Inc.)"></img>
                        </a>
                </p>
    </div>
<p xmlns="http://www.w3.org/1999/xhtml">The Company was selected a Platinum award winner in the Innovator in Biotech Solutions Category. INT230-6, Intensity&#39;s lead proprietary investigational product candidate, is designed for direct intratumoral injection. The drug consists of two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate, and a diffusion and cell penetration enhancer molecule (&#34;SHAO&#34;) that non-covalently conjugates to the two payload drugs, facilitating the dispersion of potent cytotoxic drugs throughout tumors and allowing the active agents to diffuse into cancer cells. INT230-6 is being developed in combination with standard-of-care therapies to improve the durability of response across multiple solid tumor indications.</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;The recognition from the Pinnacle Award is a testament to Intensity&#39;s commitment to changing the future of cancer care,&#34; said Intensity Therapeutics Co-Founder and CEO Lewis H. Bender. &#34;INT230-6 represents a new, unique methodology for cancer cell death that holds the potential to shift the cancer treatment from a short-term death sentence to chronic diseases, even for malignancies that are unresponsive to immunotherapy.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">The Pinnacle Awards is an esteemed annual awards program dedicated to recognizing and celebrating outstanding achievements across various industries. Its mission is to honor companies, products, and individuals that have demonstrated exceptional innovation, creativity, and impact in their fields. Each year, nominees are evaluated by industry experts, media professionals, and consultants who ensure that only the most deserving candidates receive recognition.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About Intensity Therapeutics</b></p><p xmlns="http://www.w3.org/1999/xhtml">Intensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor&#39;s dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity&#39;s clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases even for malignancies that do not respond to conventional immunotherapy. Intensity has completed two clinical studies that enrolled over 200 patients using INT230-6: a Phase 1/2 dose escalation study in metastatic cancers including sarcomas (NCT03058289), and a Phase 2 randomized control clinical trial in locally advanced breast cancer (the &#34;INVINCIBLE-2 Study&#34;) (NCT04781725) in women without undergoing chemotherapy prior to their surgery. The Company initiated a Phase 3 trial in soft tissue sarcoma (the &#34;INVINCIBLE-3 Study&#34;) (NCT06263231), testing INT230-6 as second or third-line monotherapy compared to the SOC with overall survival as an endpoint. Intensity also initiated a Phase 2 study in collaboration with The Swiss Group for Clinical Cancer Research, formerly SAKK, now the Swiss Cancer Institute (the &#34;INVINCIBLE-4 Study&#34;) (NCT06358573) as part of a Phase 2/3 program evaluating INT230-6 followed by the SOC immunochemotherapy and the SOC alone for patients with presurgical triple-negative breast cancer. The pathological complete response rate is the endpoint. For more information about Intensity, including publications, papers, and posters about its novel approach to cancer therapeutics, visit <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.intensitytherapeutics.com" rel="nofollow">www.intensitytherapeutics.com</a> or review our SEC filings.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</b></p><p xmlns="http://www.w3.org/1999/xhtml">Certain statements in this press release may constitute &#34;forward-looking statements&#34; within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Company&#39;s expected future plans, cash runway, development activities, projected milestones, business activities or results. When or if used in this communication, the words &#34;may,&#34; &#34;could,&#34; &#34;should,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;predict&#34; and similar expressions and their variants, as they relate to the Company or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management&#39;s current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the initiation, timing, progress and results of future preclinical studies and clinical trials and research and development programs; the need to raise additional funding before the Company can expect to generate any revenues from product sales; plans to develop and commercialize product candidates; the timing or likelihood of regulatory filings and approvals; the ability of the Company&#39;s research to generate and advance additional product candidates; the risk that product candidates that appear promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials; the implementation of the Company&#39;s business model, strategic plans for the Company&#39;s business, product candidates and technology; commercialization, marketing and manufacturing capabilities and strategy; the rate and degree of market acceptance and clinical utility of the Company&#39;s system; the Company&#39;s competitive position; the Company&#39;s intellectual property position; developments and projections relating to the Company&#39;s competitors and its industry; the Company&#39;s ability to maintain and establish collaborations or obtain additional funding; expectations related to the use of cash and cash equivalents and investments; our potential inability to satisfy the Nasdaq Capital Market&#39;s requirements for continued listing and be subject to delisting; estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other risks described in the section entitled &#34;Risk Factors&#34; in the Company&#39;s Annual Report on Form 10-K for the year ended December 31, 2024 and in the Company&#39;s subsequent SEC ﬁlings, which can be obtained on the SEC website at <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.sec.gov" rel="nofollow">www.sec.gov</a>. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management&#39;s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Investor Relations Contact:</b></p><p xmlns="http://www.w3.org/1999/xhtml">Justin Kulik<br xmlns="http://www.w3.org/1999/xhtml"></br>CORE IR<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:INTS@coreir.com" target="_blank" rel="nofollow">INTS@coreir.com<br xmlns="http://www.w3.org/1999/xhtml"></br></a>(516) 222-2560</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Media Contact:</b></p><p xmlns="http://www.w3.org/1999/xhtml">Matt Cossel<br xmlns="http://www.w3.org/1999/xhtml"></br>CORE IR<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:pr@coreir.com" target="_blank" rel="nofollow">pr@coreir.com</a></p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=NE34373&amp;sd=2026-04-15"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/intensity-therapeutics-recognized-with-pinnacle-award-for-excellence-in-healthcare-innovation-302742689.html" target="_blank">https://www.prnewswire.com/news-releases/intensity-therapeutics-recognized-with-pinnacle-award-for-excellence-in-healthcare-innovation-302742689.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE Intensity Therapeutics Inc.</p>

Intensity Therapeutics has been awarded the 2026 Pinnacle Award for its innovative intertumoral injection platform and lead candidate, INT230-6. This recognition may enhance investor confidence and help solidify the company’s position in the competitive biotechnology market.

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News